OTCMKTS:TBGNF Oxurion (TBGNF) Stock Price, News & Analysis $0.17 0.00 (0.00%) (As of 09/19/2023) Add Compare Share Share Stock Analysis Stock Analysis Get Oxurion alerts: Email Address About Oxurion Stock (OTCMKTS:TBGNF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oxurion alerts:Sign Up Key Stats Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.1752-Week Range$0.17▼$0.29VolumeN/AAverage Volume440 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.Read More… Must-Know for Trading Options (Ad)Options are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.So make sure you claim your free seat by clicking here now. Receive TBGNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxurion and its competitors with MarketBeat's FREE daily newsletter. Email Address TBGNF Stock News HeadlinesOXURION: Oxurion: Progress in the Fight Against Age-Related Macular DegenerationSeptember 14, 2024 | finanznachrichten.deOXURION: Oxurion: Progress in the Fight Against AMDSeptember 12, 2024 | finanznachrichten.deAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?September 20, 2024 | InvestorPlace (Ad)Oxurion: Progress in the Fight Against AMDSeptember 12, 2024 | actusnews.comOXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities LLCSeptember 4, 2024 | finanznachrichten.deOxurion Share ConsolidationJuly 25, 2024 | uk.finance.yahoo.comOxurion NV: Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMDMay 6, 2024 | finanznachrichten.deOxurion NV: Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program: Eleventh tranche fully issued and paid-upApril 10, 2024 | finanznachrichten.deSee More Headlines TBGNF Stock Analysis - Frequently Asked Questions How have TBGNF shares performed this year? Oxurion's stock was trading at $0.17 at the beginning of 2024. Since then, TBGNF shares have increased by 0.0% and is now trading at $0.17. View the best growth stocks for 2024 here. How do I buy shares of Oxurion? Shares of TBGNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:TBGNF CUSIPN/A CIKN/A Webwww.oxurion.com Phone(321) 675-1317FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (OTCMKTS:TBGNF) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxurion NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxurion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.